Oracle v5.2 — AI Therapeutic Intelligence

⬡ Disease or Target

Disease / Molecular Target

Patient Context (optional)

◈ Multi-Modality Analysis

Analysing…

⬡

Enter a disease or target to see modality recommendations
All therapeutic options compared — cell therapy, biologics, gene therapy, small molecule, RNA, peptide.

⬢ Selected Modality Deep-Dive

Generating deep-dive…

⬢

Run a Disease Analysis (Tab 1) and select a modality from the comparison
to drill into mechanism, development pathway, and IND strategy.

Continue to:

◆ Novelty Engine

Proposes evidence-grounded novel therapeutic hypotheses — potential new targets and molecules — by pulling current research from PubMed, ClinicalTrials.gov, and patent databases, then reasoning over what that literature implies. Every suggestion is anchored to real citations, scored for confidence, and flagged for novelty. It does not invent findings.

Indication / Disease *

Target class

Preferred modality

Literature recency

Paid feature. The Novelty Engine runs on live literature retrieval + AI synthesis and requires an active subscription.

◆ Novel Therapeutic Hypotheses

Retrieving evidence…

◆

Enter an indication to generate evidence-grounded novel therapeutic hypotheses
Each suggestion cites its sources, carries a confidence score, and is flagged as novel, partially explored, or already existing.

◎ Modality & Context

Modality / Product Type

Source / Origin

Stage / Manufacturing Step

Special Notes

◎ QC Profile + Risk Assessment

Generating QC profile…

Generate CMC detail:

◎

Select a modality to see release criteria with RAG risk scoring
Cell therapy, biologics, gene therapy, small molecule, and RNA all supported.

QC report ready. (carries the release criteria forward into the plan)

⬗ Manufacturing Input

Modality / Cell Type

Product Name

Indication

Target Scale

Target Dose / Batch

GMP Level

Special Requirements

⬗ Printable Manufacturing Plan

Building manufacturing plan…

⬗

Select modality + scale to generate a full printable manufacturing plan
Includes process flow, unit operations, equipment, release specs, scale-up, and RAG risk assessment.

Send to:

🔑 Connection

Generation runs securely through Cell Technologies AI. Use Test connection to verify.

⚙ Customizing Oracle

Tell Oracle about your company, your focus areas, and the style of output you prefer. This guidance is applied automatically to every Oracle analysis and saved to your account.

Company / Team Context

Preferred Therapeutic Areas

Style & Tone Preferences

ℹ About Oracle v5.2

Oracle v5.2 — AI Therapeutic Intelligence

Two entry modes — Disease-first or Market-first (ranked by unmet need)
Multi-modality analysis — compares cell therapy, biologics, gene therapy, small molecule, RNA, and peptide options for any disease
Printable manufacturing plan — full structured plan with process flow, unit ops, equipment, release specs, and scale-up roadmap
RAG risk assessment — color-coded risk scoring on QC parameters and manufacturing steps with on-demand detail and concrete de-risking actions
One-click handoff to Delfi — send Oracle output directly into Delfi's Trial Design generator

Important — Please read. Cell Technologies' AI tools generate analyses, risk assessments, and recommendations using artificial intelligence. Despite automated auditing and quality controls, AI-generated output can contain errors, omissions, or inaccuracies. All output is provided for informational and decision-support purposes only and does not constitute regulatory, legal, medical, or scientific advice. Users must independently verify all information — including risk ratings, regulatory references, manufacturing parameters, and clinical recommendations — against primary sources and qualified professional judgment before relying on it or making any decision. Cell Technologies accepts no liability for any actions taken or decisions made on the basis of this output, and provides the platform without warranty of any kind. By using this platform you acknowledge and accept these terms.